Study identifies new target to improve ulcerative colitis treatments

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease in which persistent mucosal inflammation damages the epithelial barrier. Intestinal macrophages help maintain homeostasis, but inflammatory pressure can shift them toward damaging phenotypes. IL-10 is a key repair signal: defects in IL-10 or its receptor can cause severe early-onset enterocolitis, and macrophage-derived IL-10 supports barrier restitution. Macrophage function depends on mitochondrial energy metabolism and quality control, and impaired mitophagy can accumulate damaged mitochondria, raise reactive oxygen species (ROS), and amplify inflammation. KARAP (killer cell activating receptor-associated protein) has been linked to immune-mediated diseases, yet how it controls macrophage mitochondrial fitness and IL-10 in UC remained unclear. Given these challenges, in-depth research is needed to define how KARAP regulates macrophage mitochondrial quality control and IL-10 production in UC.

Published (DOI: 10.1093/pcmedi/pbag027) in Precision Clinical Medicine on 25 September 2026, this study from researchers at the Affiliated Hospital of Jining Medical University and Jining Medical University examined human UC samples and a DSS-induced mouse colitis model. The team combined Tyrobp^−/− mice (KARAP-deficient), macrophage RNA sequencing, mitochondrial and mitophagy assays, and macrophage-epithelial cocultures with functional barrier readouts to test whether KARAP controls barrier repair through IL-10. The work links patient observations to mechanistic experiments.

In patient peripheral blood mononuclear cells (PBMCs), TYROBP mRNA was higher in UC than in healthy controls and correlated positively with C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). KARAP was especially high in CD14⁺ (cluster of differentiation 14-positive) monocytes/macrophages and in inflamed colonic tissue, where it colocalized with F4/80⁺ macrophages. In DSS-treated mice, KARAP deficiency reduced weight loss, colon shortening, inflammatory infiltration, and serum interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), while increasing tight-junction proteins zonula occludens-1 (ZO-1) and Occludin. Macrophage RNA sequencing showed upregulated cytokine pathways; interleukin-22 (IL-22) rose, but IL-10 showed the strongest difference.

Tyrobp^−/− macrophages produced more IL-10. Mitochondrial mass was unchanged, yet MitoSOX signals fell, membrane potential was better preserved, and adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD⁺) levels rose. Seahorse analysis showed higher basal respiration, maximal respiration, and spare respiratory capacity. Mitophagy was enhanced, with increased microtubule-associated protein 1 light chain 3 alpha/beta-II (LC3A/B-II), reduced P62, increased PTEN-induced kinase 1 (PINK1), and lower AKT (protein kinase B)/mTOR phosphorylation. The mTOR activator MHY1485 reversed these mitochondrial and IL-10 benefits. In cocultures, Tyrobp^−/− macrophages increased epithelial ZO-1/Occludin and transepithelial electrical resistance (TEER) and reduced permeability; anti-IL-10 antibody abolished these effects. These data connect clinical KARAP elevation to macrophage metabolic and repair defects.

The authors said the findings place KARAP at a practical crossroads between immune signaling and macrophage metabolism. Guangxi Zhou, a corresponding author, said blocking KARAP may help macrophages keep healthier mitochondria, produce more IL-10, and support epithelial repair during colitis. They cautioned that the evidence is preclinical and that human studies will be needed to confirm safety and efficacy. They said the next step is to test whether this pathway can be targeted selectively in inflamed gut tissue without broadly disrupting immune defense.

The study suggests KARAP could become a macrophage-directed target for UC, especially for patients who need better mucosal healing beyond symptom control. A KARAP-mTOR-mitophagy-IL-10 axis may also help explain why some inflamed guts fail to restore the epithelial barrier. Practical applications could include KARAP-blocking antibodies, small molecules, or locally delivered agents designed to act in the inflamed colon while limiting systemic immune effects. Before clinical translation, researchers will need human tissue validation, dose and safety studies, and trials measuring endoscopic healing, barrier function, and durable remission. For now, the findings offer a mechanistic roadmap rather than a ready-made therapy. They also point to mitochondrial quality control as a measurable readout for future trials.